Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Continued Democratization of Personalized Healthcare

A show of hands: How many people were adept at taking an in-home health test before the pandemic? The answer: probably not many. The pandemic changed that, along with so many other healthcare processes. Taking a COVID test, a healthcare assessment, or even a virtual patient visit weren’t things most were used to doing at…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

A show of hands: How many people were adept at taking an in-home health test before the pandemic? The answer: probably not many. The pandemic changed that, along with so many other healthcare processes. Taking a COVID test, a healthcare assessment, or even a virtual patient visit weren’t things most were used to doing at home a few short years ago, but the experience taught millions of people a valuable lesson: personalized healthcare is essential and should be a part of the healthcare journey moving forward.

Technology is leading the way in democratizing personalized healthcare. Wearable technology, from fitness monitoring to biosensors, can give patients and providers valuable health information and provide new tools for improving health outcomes. Advanced data gathering creates health equity for everyone.

David Kemp, host of Highway to Health, spoke with two women working on the front lines of that personalized healthcare mission. Sherlock Biosciences’ Julie Garlikov, Chief Commercial Officer, and Karen Davies, Chief Development Officer, gave Kemp a window into the science behind molecular diagnostics, which is changing the game of testing to a more democratized and decentralized approach to personalized healthcare.

What types of testing does Sherlock Biosciences do?

“We’re a pre-commercial company looking at the intersection of our chemistries and technologies and where our tests perform the best,” Garlikov said. “And then we talked with many consumers to understand where they want to test and what they want to test for at home. And when we put those two together, the intersection is in the areas of respiratory and sexual health. And when I say respiratory, I’m not just talking COVID tests. I’m talking about flu, or RSV, or even, in the future, strep throat, or walking pneumonia.”

Kemp’s conversation with Garlikov and Davies includes the following:

  • Creating efficiencies through at-home testing
  • The advancing technologies creating these new testing solutions
  • The importance of advanced diagnostics for rural and underserved communities

“Accessibility is the big thing,” Davies said. “And portability. A small, easy-to-run test; you can stick it in your backpack, you can stick it in your suitcase, or you can mail order it if you live in a remote region. If I’ve got that test in my backpack or I’ve got that test at home, I can run it. It’s negative most of the time. And so I can provide self-care. If it’s positive, I know it’s worth the trip to see my doctor.”

About Karen

Karen Davies is a mechanical engineer with a BS from Stanford University. Her twenty-plus-year career in medical devices includes product development, technical leadership, program management, quality and regulatory compliance, and strategic planning. She is a sought-out mentor by personnel in multiple functional areas, including Instrumentation, Assay Development, and Marketing.

About Julie

Julie Garlikov is a full-stack, omnichannel, B2C/B2B marketing & commercialization executive with numerous successes in accelerating growth for digital consumer healthcare and health, wellness & beauty (skincare, vitamins, nutrition), and beverage brands. Her passion lies in building and scaling brands to take them to the next level. Garlikov holds an MBA in marketing from Columbia Business School and a BA from the University of California, Berkeley.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512